Bolt Biotherapeutics, Inc.
BOLT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001641281
In the last 90 days, Bolt Biotherapeutics, Inc. insiders filed 2 open-market purchases and 3 sales; 23 institutions reported holding it in 13F filings for Q2 2026, worth $2.31M in total; no superinvestor holds it.
13F holders, Q4 2024
Institutional positions in Bolt Biotherapeutics, Inc. as of Dec 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 38
- +6 vs. Q3 2024
- Shares held
- 18.7M
- −127.2K (−0.7%) vs. Q3 2024
- Total value
- $9.99M
- −$2.18M (−17.9%) vs. Q3 2024
- New holders
- 11
- 6 more added
- Sold out
- 5
- 6 more reduced
Compare with Q3 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting BOLT on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 23 | $2.31M |
| Q1 2026 | 24 | $2.49M |
| Q4 2025 | 21 | $3.30M |
| Q3 2025 | 24 | $4.28M |
| Q2 2025 | 25 | $5.10M |
| Q1 2025 | 30 | $7.33M |
| Q4 2024 | 38 | $9.99M |
| Q3 2024 | 32 | $12.2M |
| Q2 2024 | 37 | $17.0M |
| Q1 2024 | 39 | $33.6M |
| Q4 2023 | 40 | $27.0M |
| Q3 2023 | 35 | $25.5M |
| Q2 2023 | 40 | $32.1M |
| Q1 2023 | 41 | $32.4M |
| Q4 2022 | 44 | $26.8M |
| Q3 2022 | 56 | $39.7M |
| Q2 2022 | 62 | $54.8M |
| Q1 2022 | 66 | $79.3M |
| Q4 2021 | 62 | $164.6M |
| Q3 2021 | 72 | $449.1M |
| Q2 2021 | 61 | $513.8M |
| Q1 2021 | 70 | $1.04B |
Institutions, Q4 2024
Shares, value and share of portfolio for each institution holding Bolt Biotherapeutics, Inc.; share changes are against Q3 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Tang Capital Management LLC | 3,812,773 | $2.04M | 0.13% | 00.0% | Unchanged |
| Vivo Capital, LLC | 3,521,291 | $1.88M | 0.21% | 00.0% | Unchanged |
| Sofinnova Investments, Inc. | 2,754,437 | $1.47M | 0.11% | 00.0% | Unchanged |
| Pivotal bioVenture Partners Investment Advisor LLC | 1,891,467 | $1.02M | 0.69% | 00.0% | Unchanged |
| Nan Fung Group Holdings Ltd | 1,166,952 | $624.4K | 0.53% | 00.0% | Unchanged |
| Vanguard Group Inc | 1,067,405 | $571.1K | 0.00% | 00.0% | Unchanged |
| Samsara BioCapital, LLC | 1,049,153 | $561.4K | 0.08% | 00.0% | Unchanged |
| Board of Trustees of The Leland Stanford Junior University | 719,546 | $385.0K | 0.03% | 00.0% | Unchanged |
| Pfizer Inc | 626,109 | $335.0K | 0.01% | +626,109 | New |
| Geode Capital Management, LLC | 340,674 | $182.3K | 0.00% | −11,752−3.3% | Reduced |
| Renaissance Technologies LLC | 302,039 | $161.6K | 0.00% | +8,000+2.7% | Added |
| BlackRock, Inc. | 270,092 | $144.5K | 0.00% | +484+0.2% | Added |
| ADAR1 Capital Management, LLC | 244,966 | $131.1K | 0.03% | 00.0% | Unchanged |
| FMR LLC | 129,254 | $69.2K | 0.00% | +13,868+12.0% | Added |
| Citadel Advisors LLC | 78,961 | $42.3K | 0.00% | +78,961 | New |
| Engineers Gate Manager LP | 72,402 | $38.7K | 0.00% | +72,402 | New |
| UBS Group AG | 66,113 | $35.4K | 0.00% | +30,816+87.3% | Added |
| Bridgeway Capital Management, LLC | 60,200 | $32.2K | 0.00% | 00.0% | Unchanged |
| Goldman Sachs Group Inc | 50,020 | $26.8K | 0.00% | +50,020 | New |
| Velan Capital Investment Management LP | 50,000 | $26.8K | 0.02% | +50,000 | New |
| Squarepoint Ops LLC | 48,971 | $26.2K | 0.00% | +48,971 | New |
| State Street Corp | 47,437 | $25.4K | 0.00% | 00.0% | Unchanged |
| Millennium Management LLC | 47,025 | $25.2K | 0.00% | +47,025 | New |
| XTX Topco Ltd | 44,891 | $24.0K | 0.00% | +44,891 | New |
| Jane Street Group, LLC | 41,868 | $22.4K | 0.00% | +13,766+49.0% | Added |
| Northern Trust Corp | 40,895 | $21.9K | 0.00% | 00.0% | Unchanged |
| Mariner, LLC | 35,000 | $18.7K | 0.00% | −5,535−13.7% | Reduced |
| Virtu Financial LLC | 29,552 | $16.0K | 0.00% | +29,552 | New |
| Assenagon Asset Management S.A. | 20,785 | $11.1K | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 11,616 | $6.22K | 0.00% | −11,833−50.5% | Reduced |
| Bank of America Corp | 5,625 | $3.01K | 0.00% | −375−6.3% | Reduced |
| Tower Research Capital LLC (TRC) | 4,008 | $2.14K | 0.00% | +3,824+2,078.3% | Added |
| Advisor Group Holdings, Inc. | 2,355 | $1.27K | 0.00% | −15,000−86.4% | Reduced |
| JPMorgan Chase & Co | 911 | $487 | 0.00% | −3−0.3% | Reduced |
| SBI Securities Co., Ltd. | 200 | $107 | 0.00% | +200 | New |
| Barclays PLC | 139 | $74 | 0.00% | 00.0% | Unchanged |
| Salem Investment Counselors Inc | 40 | $22 | 0.00% | 00.0% | Unchanged |
| BNP Paribas Arbitrage, SA | 1 | $1 | 0.00% | +1 | New |
| Adage Capital Partners GP, L.L.C. | 0 | $0 | 0.00% | −500,000−100.0% | Sold out |
| Newtyn Management, LLC | 0 | $0 | 0.00% | −468,910−100.0% | Sold out |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −147,926−100.0% | Sold out |
| Prudential Financial Inc | 0 | $0 | 0.00% | −59,200−100.0% | Sold out |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −25,509−100.0% | Sold out |